An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: Systematic review

BMJ Open

Volumn 5, Issue 1, 2015, Pages

  Norman, Gill ^a   Fayter, Debra ^a   Lewis Light, Kate ^a   Chisholm, Julia ^b   McHugh, Kieran ^c   Levine, Daniel ^b   Jenney, Meriel ^d   Mandeville, Henry ^b   Gatz, Suzanne ^b   Phillips, Bob ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d CHILDREN S HOSPITAL FOR WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; EVIDENCE BASED PRACTICE; HUMAN; POSITRON EMISSION TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RHABDOMYOSARCOMA; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; CANCER STAGING; CHILD; COMPUTER ASSISTED TOMOGRAPHY; EVIDENCE BASED MEDICINE; PROCEDURES; STANDARDS;

RADIOPHARMACEUTICAL AGENT;

CHILD; DIFFUSION MAGNETIC RESONANCE IMAGING; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RHABDOMYOSARCOMA; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84920749543     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006030     Document Type: Review

References (44)

1. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. Bethesda, MD: National Cancer Institute, 1999.
2. West Midlands Cancer Intelligence Unit. Soft tissue sarcomas: incidence and survival rates in England. The National Cancer Intelligence Network, 2011 (cited 04 March 2014). http://www.ncin. org.uk/publications/data-briefings/soft-tissue-sarcoma
3. Chisholm JC, Marandet J, Rey A, et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 2011;29:1319-25.
4. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008;26:2384-9.
5. Weiss AR, Lyden ER, Anderson JR, et al. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol 2013;31:3226-32.
6. Schoot RA, McHugh K, van Rijn RR, et al . Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments? Radiology 2013;269:870-8.
7. Facey K, Bradbury I, Laking G, et al. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007;11:1-288.
8. Brush J, Boyd K, Chappell F, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess 2011;15:1-192.
9. Cooper KL, Meng Y, Harnan S, et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. Health Technol Assess 2011;15: iii-iv, 1-134.
10. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas: a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83-101.
11. Institute for Quality and Efficiency in Health Care (Germany). Positron emission tomography (PET) in bone and soft tissue tumors (Preliminary Report). Cologne, Germany: IQWiG, 2012.
12. Fayter D, Norman G, Phillips B, et al. A systematic review of the clinical effectiveness of advanced functional imaging assessment in children and young people with rhabdomyosarcoma. PROSPERO. 2013:CRD42013006128.
13. Maund E, Craig D, Suekarran S, et al. Management of frozen shoulder: a systematic review and cost-effectiveness analysis. Health Technol Assess 2012;16:1-264.
14. Norman G, Llewellyn A, Harden M, et al. Systematic review of the limited evidence base for treatments of Eustachian tube dysfunction: a health technology assessment. Clin Otolaryngol 2014;39:6-21.
15. Adams MC, Turkington TG, Wilson JM, et al. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 2010;195:310-20.
16. Eugene T, Corradini N, Carlier T, et al. 18F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. Nucl Med Commun 2012;33:1089-95.
17. Dharmarajan KV, Wexler LH, Gavane S, et al. Positron emission tomography (PET) evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2012;84:996-1002.
18. Federico SM, Wu J, Spunt SL, et al. Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. Pediatr Blood Cancer 2012;60:1128-34.
19. Tateishi U, Hosono A, Makimoto A, et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med 2009;23:155-61.
20. Volker T, Denecke T, Steffen I, et al . Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007;25:5435-41.
21. Ricard F, Cimarelli S, Deshayes E, et al. Additional benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med 2011;36:672-7.
22. Baum SH, Fruhwald M, Rahbar K, et al. Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma. J Nucl Med 2011;52:1535-40.
23. Klem ML, Grewal RK, Wexler LH, et al. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 2007;29:9-14.
24. Eugene T, Ansquer C, Oudoux A, et al. FDG PET/CT in initial staging and early response to chemotherapy assessment of paediatric rhabdomyosarcomas. Medecine Nucleaire 2010;34:655-63.
25. Dharmarajan KV, Wexler LH, Tom A, et al. Positron emission tomography (PET) response to initial chemotherapy and radiation therapy (RT) predicts local control in rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2011;1:S116.
26. Ricard F, Cimarelli S, Deshayes E, et al. Utility of FDG PET/CT in childhood rhabdomyosarcoma. Eur J Nucl Med Mol Imaging 2010;37:S443.
27. McCarville B, Krasin M, Spunt S, et al. PET/CT in pediatric rhabdomyosarcoma. Pediatr Radiol 2011;41:S272.
28. Tateishi U, Yamaguchi U, Seki K, et al. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 2007;245:839-47.
29. Krasin M, Hua C, Spunt SL, et al. FDG-PET/CT prior or subsequent to radiation is a poor predictor of local outcome in patients with group III rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2011;1: S116.
30. Federico S, McCarville B, Spunt S, et al. Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. Pediatr Blood Cancer 2012;58:1018.
31. Nguyen JQ, Davis K, Mittra ES, et al. Clinical utility of 18F FDG PET/CT and 99mTc MDP bone scintigraphy in patients with Ewings sarcoma and other sarcomas. Clin Nucl Med 2011;36:620.
32. Dziuk M, Raciborska A, Bilska K, et al. The value of FDG PET-CT scanning in restaging of the sarcoma in children. Eur J Nucl Med Mol Imaging 2010;37:S252.
33. Abdel Razek AAK, Gaballa G, Elhawarey G, et al. Characterization of pediatric head and neck masses with diffusion-weighted MR imaging. Eur Radiol 2009;19:201-8.
34. Lope LA, Hutcheson KA, Khademian Z. Diffusion weighted imaging in the analysis of pediatric orbital tumors. J AAPOS 2009;13:e7.
35. Humphries PD, Sebire NJ, Siegel MJ, et al. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 2007;245:848-54.
36. Kocaoglu M, Bulakbasi N, Sanal HT, et al. Pediatric abdominal masses: diagnostic accuracy of diffusion weighted MRI. Magn Reson Imaging 2010;28:629-36.
37. Neubauer H, Evangelista L, Hassold N, et al. Diffusion-weighted MRI for detection and differentiation of musculoskeletal tumorous and tumor-like lesions in pediatric patients. World J Pediatr 2012;8:342-9.
38. Oka K, Yakushiji T, Sato H, et al . Ability of diffusion-weighted imaging for the differential diagnosis between chronic expanding hematomas and malignant soft tissue tumors. J Magn Reson Imaging 2008;28:1195-200.
39. Roshdy N, Shahin M, Kishk H, et al. MRI in diagnosis of orbital masses. Curr Eye Res 2010;35:986-91.
40. Norman G, Fayter D, Lewis-Light K, et al. Mind the gap: extent of use of diffusion-weighted MRI in children with rhabdomyosarcoma. Pediatric Radiology [Epub ahead of print Sept 2014]. doi:0.1007/ s00247-014-3120-z.
41. Hayes-Jordan A, Andrassy R. Rhabdomyosarcoma in children. Curr Opin Pediatr 2009;21:373-8.
42. Phillips B, Stewart LA, Suttona AJ. 'Cross hairs' plots for diagnostic meta-analysis. Res Synth Methods 2011;1:308-15.
43. Quartuccio N, Treglia G, Salsano M, et al. The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiol Oncol 2013;47:97-102.
44. Barger RL, Nandalur KR. Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. Acad Radiol 2012;19:153-8.